Publications by authors named "Radovan Tomic"

Claim this Profile
C
Cost-effectiveness and cost-utility analysis of Haemate-P versus other von Willebrand disease treatments in Spain.
Juan E Megias-Vericat, Gines Escolar, Michele R Wilson, Pablo Mendez, Cheryl L McDade, Radovan Tomic

J Med Econ· December 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Comparing Real-World Outcomes of Prophylaxis with Extended Half-life Factor IX (rIX-FP vs. rFIXFc and N9-GP) for Haemophilia B: An Analysis of Medical Chart Data from Germany.
Martin Olivieri, Songkai Yan, Ying Yang, Radovan Tomic, Thomas Linhoff

Adv Ther· November 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-World Prophylaxis Outcomes with rIX-FP and rFIXFc for Males with Hemophilia B: Pooled Analysis of Medical Chart Data from Germany and Italy.
Johannes Oldenburg, Martin Olivieri, Songkai Yan, Ying Yang, Radovan Tomic

Adv Ther· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness of Voncento prophylaxis vs on-demand treatment in von Willebrand disease in the United Kingdom.
Michele Wilson, Giancarlo Castaman, Will Thomas, Carolyn Millar, Ginés Escolar, Radovan Tomic

Blood Adv· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic model-based assessment of factor IX prophylaxis treatment regimens in severe hemophilia B.
Björn Vandewalle, Giancarlo Castaman, Maria Teresa Álvarez-Román, Carmen Escuriola Ettingshausen, László Nemes, Radovan Tomic

Sci Rep· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Classification of recombinant factor VIII products and implications for clinical practice: A systematic literature review.
Cihan Ay, Mariasanta Napolitano, Abel Hassoun, Radovan Tomic, Cedric Martin

Haemophilia· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Matching-Adjusted Indirect Comparison of Recombinant Factor IX Albumin Fusion Protein Versus Recombinant Factor IX Fc Fusion Protein for Weekly Prophylactic Treatment of Hemophilia B.
Benoit Guillet, Songkai Yan, Becky Hooper, Douglass Drelich, Jason Steenkamp, Radovan Tomic

Adv Ther· February 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Budget impact of prophylactic treatment of rVIII-SingleChain in moderate and severe hemophilia A in Italy.
Eugenio Di Brino, Songkai Yan, Radovan Tomic, Marco Panebianco, Ewa Dlotko

J Med Econ· April 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Analysis of pooled real-world data from Germany, Italy, and the United States of rVIII-SingleChain compared with standard- and long-acting FVIII products for prophylaxis of hemophilia A.
Martin Olivieri, Mindy Simpson, Songkai Yan, Johanna Fedorovsky, Xiang Zhang, Radovan Tomic

Curr Med Res Opin· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Statin utilization and lipid goal attainment in high or very-high cardiovascular risk patients: Insights from Italian general practice.
Marcello Arca, David Ansell, Maurizio Averna, Francesca Fanelli, Katherine Gorcyca, Radovan Tomic

Atherosclerosis· April 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis